Title:Personalized Approaches to Cardiovascular Disease: Insights into
FDA-Approved Interventions and Clinical Pharmacogenetics
Volume: 30
Issue: 21
Author(s): Ramin Raoufinia, Hamid Reza Rahimi, Mahla Abbaszadeh, Aida Gholoobi, Ehsan Saburi, Farhad Fakoor, Hawraa Ibrahim Alshakarchi, Ibrahim Saeed Gataa, Seyed Mahdi Hassanian, Gordon A. Ferns, Majid Khazaei and Amir Avan*
Affiliation:
- Medical Genetics Research
Center, Mashhad University of Medical Sciences, Mashhad, Iran
- Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad,
Iran
- Faculty of Health, School of Biomedical Sciences, Queensland University of Technology (QUT), Brisbane
4059, Australia
Keywords:
Personalized medicine, cardiovascular diseases, FDA-approved interventions, clinical pharmacognetics, quality of life, heart conditions.
Abstract: Cardiovascular diseases place a considerable burden on global health systems, contributing to high
rates of morbidity and mortality. Current approaches to detecting and treating Cardiovascular Diseases (CVD)
often focus on symptomatic management and are initiated after the disease has progressed. Personalized
medicine, which tailors medical interventions to individual characteristics, has emerged as a promising strategy
for improving cardiovascular health outcomes. This article provides an overview of personalized medicine
in the context of CVD, with a specific emphasis on FDA-approved interventions. It explores the potential benefits,
challenges, and future directions of personalized medicine in cardiovascular disorders. By reviewing the
advancements in this field, this article underscores the importance of early detection, intervention, and innovative
treatment options in reducing the impact of CVD on individuals and society.
